

ADDF-HARRINGTON SCHOLAR AWARD

FUNDING OPPORTUNITY

OVERVIEW


The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute have partnered to accelerate the translation of academic discoveries into medicines for **treating, preventing, or curing patients with Alzheimer's disease and related dementias.**

SUCCESSFUL APPLICANTS WILL RECEIVE:

- Guaranteed \$100,000 grant award for two years
- Support from the Harrington Therapeutics Development Center for two years
- Opportunity to qualify for investment funds
- **NOTE: IP rights are retained by the awardee or their institution.**

THE HARRINGTON ADVANTAGE

A personalized therapeutics development team, including former leaders from the pharma industry and a dedicated project manager, surrounds each Scholar with expertise to de-risk and advance their discovery towards the clinic.



PROPOSALS OF INTEREST



- Novel, validated targets
- Any therapeutic modality
- Discoveries demonstrating rigorous science, creativity, innovation and potential for clinical impact

ELIGIBILITY

MD or PhD (or equivalent) researchers in the US, Canada and UK

IMPORTANT DATES

March 9, 2026 | Call opens

June 1, 2026 | LOI deadline

August 17, 2026 | Application deadline for those invited

March 2027 | Notification of award

LEARN MORE AND APPLY

HarringtonDiscovery.org/ADDF-Harrington

QUESTIONS?

Questions@HarringtonDiscovery.org

Harrington Discovery Institute

 University Hospitals | Cleveland, Ohio



Alzheimer's
Drug Discovery
Foundation

© 2026 University Hospitals

Harrington Discovery Institute® is a registered U.S. trademark of University Hospitals Health System, Inc., and used with permission.

Harrington Discovery Institute's granting organization in the UK is Fund for Cures UK, LTD.